Your browser doesn't support javascript.
loading
Poor outcome with anti-programmed death-ligand 1 (PD-L1) antibody due to poor pharmacokinetic properties in PD-1/PD-L1 blockade-sensitive mouse models.
Kurino, Taiki; Matsuda, Reiko; Terui, Ayu; Suzuki, Hiroyuki; Kokubo, Tomomi; Uehara, Tomoya; Arano, Yasushi; Hisaka, Akihiro; Hatakeyama, Hiroto.
Afiliação
  • Kurino T; Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
  • Matsuda R; Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
  • Terui A; Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
  • Suzuki H; Laboratory of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
  • Kokubo T; Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
  • Uehara T; Laboratory of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
  • Arano Y; Laboratory of Molecular Imaging and Radiotherapy, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
  • Hisaka A; Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan.
  • Hatakeyama H; Laboratory of Clinical Pharmacology and Pharmacometrics, Graduate School of Pharmaceutical Sciences, Chiba University, Chiba, Japan h-hatakeyama@chiba-u.jp.
J Immunother Cancer ; 8(1)2020 02.
Article em En | MEDLINE | ID: mdl-32041818
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Inibidores de Checkpoint Imunológico / Neoplasias Mamárias Experimentais Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Protocolos de Quimioterapia Combinada Antineoplásica / Antígeno B7-H1 / Receptor de Morte Celular Programada 1 / Inibidores de Checkpoint Imunológico / Neoplasias Mamárias Experimentais Tipo de estudo: Diagnostic_studies / Prognostic_studies Idioma: En Revista: J Immunother Cancer Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Japão